The inhibitor of dipeptidyl-peptidase 4 (DPP4), a GLP-1 destabilizer that is transcriptionally induced by Wnt/β-catenin signaling, prevents multiple NASH phenotypes13,14. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.